Retatrutide 20mg

Retatrutide is an experimental injectable drug developed by Eli Lilly that's being studied for weight loss and type 2 diabetes. It works as a "triple agonist," activating three different gut hormone receptors — GLP-1, GIP, and glucagon — which together appear to produce greater appetite suppression and metabolic effects than single- or dual-agonist drugs like semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound). In mid-stage clinical trials, participants have lost substantial amounts of body weight over roughly a year of treatment.
Important information: retatrutide is still in clinical trials and has not been approved by the FDA or any other regulatory agency. It is not an approved medication and is not intended for human consumption outside of controlled clinical trial settings.